查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1703477

生物共軛市場－全球產業規模、佔有率、趨勢、機會和預測，按產品（試劑和試劑盒、標籤、其他）、按應用（治療、研發、診斷）、按地區和競爭細分，2020 年至 2030 年

Bioconjugation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Reagents & Kits, Labels, Others), By Application (Therapeutics, Research & Development, Diagnostics), By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球生物共軛市場價值為 17.5 億美元，預計到 2030 年將達到 25.2 億美元，預測期內複合年成長率為 6.50%。

市場概覽
預測期 2026-2030
2024年市場規模 17.5億美元
2030年市場規模 25.2億美元
2025-2030 年複合年成長率 6.50%
成長最快的領域 試劑和試劑盒
最大的市場 北美洲

生物共軛——指兩種分子（通常是生物分子和合成化合物）的化學連接——已成為現代醫學的變革性技術。由於其增強分子功能的能力，它在製藥、生物技術、診斷和生物醫學研究等廣泛的行業中得到越來越廣泛的應用。

該市場的主要成長動力是其在標靶藥物傳遞中的關鍵作用，其中治療劑透過化學方式附著於特定的生物標記。這使得能夠精確瞄準患病細胞，同時最大限度地減少對健康組織的影響，從而提高療效並降低毒性。事實證明，這些進步在治療癌症、自體免疫疾病和傳染病方面特別有價值。隨著個人化醫療在全球的興起，對生物結合技術的需求預計將加速成長。

儘管前景光明，但市場仍面臨挑戰，特別是生物共軛化學的複雜性、高昂的開發成本和監管障礙。然而，化學合成、自動化和先進療法的需求的持續創新繼續加強市場的長期成長軌跡。隨著生物共軛技術的發展，它將在下一代治療和診斷解決方案的進步中發揮越來越重要的作用。

關鍵市場促進因素

全球醫療保健產業的擴張

主要市場挑戰

生物共軛製程成本高昂

這些成本和資源限制可能會限制小公司的可近性並阻礙其廣泛採用，尤其是在早期研發階段或新興市場。

主要市場趨勢

標靶治療需求激增

推動生物共軛市場發展的關鍵趨勢是全球對標靶治療的需求不斷成長，特別是在腫瘤學和複雜慢性病管理領域。

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球生物共軛市場的影響

第5章：全球生物共軛市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按產品（試劑和試劑盒、標籤、其他）
    • 依應用（治療學、研發、診斷學）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第6章：北美生物共軛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第7章：歐洲生物共軛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太生物共軛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第9章：南美洲生物共軛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章：中東與非洲生物共軛市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如有）
  • 最新動態

第 13 章：全球生物共軛市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 28067

Global Bioconjugation Market was valued at USD 1.75 billion in 2024 and is projected to reach USD 2.52 billion by 2030, growing at a CAGR of 6.50% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.75 Billion
Market Size 2030USD 2.52 Billion
CAGR 2025-20306.50%
Fastest Growing SegmentReagents & Kits
Largest MarketNorth America

Bioconjugation-referring to the chemical linkage of two molecules, typically a biomolecule and a synthetic compound-has emerged as a transformative technique in modern medicine. It is increasingly applied across a broad range of industries, including pharmaceuticals, biotechnology, diagnostics, and biomedical research, owing to its ability to enhance molecular functionality.

A primary growth driver for this market is its pivotal role in targeted drug delivery, where therapeutic agents are chemically attached to specific biomarkers. This enables the precise targeting of diseased cells while minimizing impact on healthy tissue, thereby improving efficacy and reducing toxicity. Such advancements have proven especially valuable in treating cancer, autoimmune disorders, and infectious diseases. With the global rise of personalized medicine, the demand for bioconjugation technologies is expected to accelerate.

Despite its promising outlook, the market faces challenges, particularly the complexity of bioconjugation chemistry, high development costs, and regulatory hurdles. However, ongoing innovations in chemical synthesis, automation, and demand for advanced therapeutics continue to reinforce the market's long-term growth trajectory. As bioconjugation evolves, it is set to play an increasingly central role in the advancement of next-generation therapeutic and diagnostic solutions.

Key Market Drivers

Expansion of the Global Healthcare Industry

The continued growth of the global healthcare sector is a significant catalyst for the bioconjugation market, driving demand for innovative diagnostics and precision therapeutics. Healthcare is among the most rapidly expanding industries worldwide, with expenditures in many developed countries exceeding 10% of GDP. For instance, the United States recorded healthcare spending of USD 4.3 trillion in 2021, accounting for 18.3% of its GDP-approximately USD 12,914 per capita.

As global healthcare systems increasingly prioritize precision medicine, targeted therapies, and advanced diagnostic technologies, bioconjugation has emerged as an enabling platform to enhance treatment efficacy and patient outcomes. In particular, its ability to chemically link biomolecules with functional agents has gained traction in the pharmaceutical and biotech sectors.

The pharmaceutical industry has seen consistent growth, reaching a valuation of approximately USD 1.6 trillion in 2023, comparable to the GDPs of countries like Mexico, Spain, and Australia. This expansion underscores the critical role of bioconjugation in supporting the development of personalized treatment modalities, especially in oncology and chronic disease care.

Antibody-drug conjugates (ADCs) exemplify the growing importance of bioconjugation. These therapies deliver cytotoxic drugs directly to cancer cells, minimizing harm to healthy tissue and improving therapeutic outcomes. As demand for such targeted solutions increases, bioconjugation is becoming a core technology across healthcare applications.

Key Market Challenges

High Costs Associated with Bioconjugation Processes

One of the key obstacles to market growth is the high cost of bioconjugation technologies. The process requires premium-quality raw materials, including antibodies, proteins, and peptides, which are expensive to produce, purify, and stabilize. Additionally, specialized chemical linkers must be carefully selected and optimized to ensure conjugate stability and efficacy-further adding to production expenses.

The requirement for advanced instrumentation also significantly contributes to operational costs. Analytical techniques such as mass spectrometry, chromatography, and high-performance liquid chromatography (HPLC) are essential for validating the conjugation process and analyzing purity and stability. Operating these tools demands both capital investment and a skilled workforce, increasing the overall financial burden on developers of new bioconjugate-based products.

These cost and resource constraints can limit accessibility for smaller companies and hinder widespread adoption, particularly in early-stage R&D or in emerging markets.

Key Market Trends

Surging Demand for Targeted Therapeutics

A key trend propelling the bioconjugation market is the growing global demand for targeted therapies, particularly in oncology and complex chronic disease management.

According to the Global Cancer Observatory (GLOBOCAN), an estimated 19.3 million new cancer cases and nearly 10 million cancer-related deaths occurred globally in 2020. By 2040, cancer incidence is projected to reach 28.4 million cases, representing a 47% increase, largely due to aging populations and lifestyle-related risk factors such as obesity and tobacco use.

This rising burden has amplified the need for more effective treatment options. Targeted therapies-designed to deliver drugs directly to diseased tissues while sparing healthy cells-are becoming the standard of care in many advanced treatment protocols. Bioconjugation is fundamental to the development of such therapies.

Antibody-drug conjugates (ADCs) are among the most prominent bioconjugated solutions in this space, particularly in oncology. By linking potent cytotoxic agents to antibodies that recognize specific cancer cell markers, ADCs offer a high degree of selectivity and efficacy, improving patient outcomes while reducing systemic toxicity.

Key Market Players

  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Sartorius AG
  • Abbvie, Inc.
  • Bio-Rad Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Catalent, Inc.
  • Becton, Dickinson and Company

Report Scope

In this report, the Global Bioconjugation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bioconjugation Market, By Product:

  • Reagents & Kits
  • Labels
  • Others

Bioconjugation Market, By Application:

  • Therapeutics
  • Research & Development
  • Diagnostics

Bioconjugation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bioconjugation Market.

Available Customizations:

Global Bioconjugation Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Bioconjugation Market

5. Global Bioconjugation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Reagents & Kits, Labels, Others)
    • 5.2.2. By Application (Therapeutics, Research & Development, Diagnostics)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Bioconjugation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bioconjugation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Bioconjugation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Bioconjugation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Bioconjugation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Bioconjugation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Bioconjugation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Bioconjugation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Bioconjugation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Bioconjugation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia Pacific Bioconjugation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bioconjugation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Bioconjugation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Bioconjugation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Bioconjugation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Bioconjugation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Bioconjugation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bioconjugation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Bioconjugation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Bioconjugation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Bioconjugation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bioconjugation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Bioconjugation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Bioconjugation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bioconjugation Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Danaher Corporation
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. Lonza Group Ltd.
  • 15.4. Merck KGaA
  • 15.5. Sartorius AG
  • 15.6. Abbvie, Inc.
  • 15.7. Bio-Rad Laboratories, Inc.
  • 15.8. Agilent Technologies, Inc.
  • 15.9. Catalent, Inc.
  • 15.10. Becton, Dickinson and Company

16. Strategic Recommendations

17. About Us & Disclaimer